{
    "organizations": [],
    "uuid": "428d4a9c44027208d898de82a6f1f352608a32c5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-shanghai-fudan-zhangjiang-bio-phar/brief-shanghai-fudan-zhangjiang-bio-pharmaceutical-expects-to-record-a-decrease-in-fy-net-profit-idUSFWN1PI0D2",
    "ord_in_thread": 0,
    "title": "BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical ‍Expects To Record A Decrease In FY Net Profit",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:\n* ‍EXPECTS TO RECORD A DECREASE IN NET PROFIT OF GROUP BY APPROXIMATELY 50% FOR FY\n* ‍EXPECTS DECREASE IN FY REVENUE OF GROUP BY APPROXIMATELY 20%\n* EXPECTED DECREASE IN REVENUE DUE TO DECREASED REVENUE FROM LIBOD BY ABOUT 50% FOR FY ENDED 31 DEC 2017​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-23T18:06:00.000+02:00",
    "crawled": "2018-01-24T15:44:06.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "shanghai",
        "co",
        "ltd",
        "record",
        "decrease",
        "net",
        "profit",
        "group",
        "approximately",
        "fy",
        "decrease",
        "fy",
        "revenue",
        "group",
        "approximately",
        "expected",
        "decrease",
        "revenue",
        "due",
        "decreased",
        "revenue",
        "libod",
        "fy",
        "ended",
        "dec",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}